Scarica l'app Stockscreener
0.00
100.00%
-1.71
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché APTO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.71
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$10.59M
Reddito:
-
Utile/perdita netta:
$-35.80M
Rapporto P/E:
0.00
EPS:
-2.97
Flusso di cassa netto:
$-37.18M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$19.80
Aptose Biosciences Inc Stock (APTO) Company Profile
Nome
Aptose Biosciences Inc
Settore
Industria
Telefono
310-849-8060
Indirizzo
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Confronta APTO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.10 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.76 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.32 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.97 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-10-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-02-20 | Iniziato | Maxim Group | Buy |
| 2020-02-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | Piper Sandler | Overweight |
| 2019-03-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-16 | Iniziato | B. Riley FBR | Buy |
| 2017-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-23 | Ripresa | ROTH Capital | Buy |
| 2017-09-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | Iniziato | Rodman & Renshaw | Neutral |
Mostra tutto
Aptose Biosciences Inc Borsa (APTO) Ultime notizie
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - The Manila Times
(APS) Comprehensive Trading Strategy Report (APS:CA) - news.stocktradersdaily.com
Aptose Announces Deferral of Interest Payment | APTOF Stock News - GuruFocus
Aptose Announces Deferral of Interest Payment - Yahoo Finance
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Provides Corporate Updates - The Manila Times
Aptose Provides Corporate Updates | APTOF Stock News - GuruFocus
Aptose CEO props up biotech's finances to prevent company from going bust - Fierce Biotech
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose's Closing of US$3M Investment by Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences completes Public Offering of Common Shares for US$74.2M - McCarthy Tétrault
Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement - McCarthy Tétrault LLP
Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility - McCarthy Tétrault
Aptose Biosciences Inc. enters into at-the-market sales agreement with Cantor Fitzgerald & Co. - McCarthy Tétrault
Aptose Biosciences Inc. closes C$8M public offering - McCarthy Tétrault LLP
Aptose enters equity distribution agreement with Piper Sandler and Canaccord Genuity - McCarthy Tétrault
Aptose Announces Results from Annual and Special Meeting of Shar - GuruFocus
Aptose Announces Results from Annual and Special Meeting of Shareholders - The Globe and Mail
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee | APTOF Stock N - GuruFocus
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - The Manila Times
(APS) Advanced Equity Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
Aptose Biosciences Inc Azioni (APTO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):